Arbutus Biopharma Corp (ABUS) income statement
ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 14/3073% below fair value
$4.11+0.06 (+1.48%)
Close on Nov 18, 2026Market cap $813.16MP/E 5.3Yield –
Arbutus Biopharma Corp financial ratios
See a number that looks wrong?